Iovance presents ESMO 2026 data showing deep, durable responses to lifileucel TIL cell therapy plus pembrolizumab in frontline advanced melanoma

Observed price moves

• IOVA-1.29%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.